Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Marina de Souza BragaMaria Helena Bellini

Abstract

Despite recent advances in targeted therapy, renal cell carcinoma (RCC) remains one of the most lethal urologic malignancies. Approximately 30% of patients with localised RCC will develop metastases after curative surgery. Presurgical therapy has been explored for treatment of localised RCC. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we examined the potential use of an antiangiogenic agent as a neoadjuvant therapy in an orthotopic metastatic mouse model of RCC. BALB/c mice bearing Renca cells were treated before nephrectomy with NIH/3T3-LendSN cells. At the end of the experiment, ES serum levels were measured. Primary and metastatic tumour area and microvascular area were determined. In the survival studies, mice were monitored daily until they died. ES serum levels in treated mice were higher in the control group (P<0.05). The median primary tumour area and the mean microvascular area were significantly lower in the ES-treated group compared to control group (P<0.05). The proliferation of Renca cells in the ES-treated group was significantly reduced compared with the control group (P<0.01). ES therapy led to a significant reduction in the number of pulmonary metastati...Continue Reading

References

Nov 7, 2003·Current Molecular Medicine·Judah Folkman
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
May 22, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Enia Lúcia CoutinhoMaria Helena Bellini
Mar 24, 2009·BJU International·Anil KapoorJ Paul Whelan
Apr 25, 2009·BJU International·Joaquim BellmuntStéphane Oudard
Sep 15, 2009·European Urology·Giuseppe Di LorenzoCora N Sternberg
Feb 11, 2010·Nature Reviews. Urology·Vincenzo Ficarra, Giacomo Novara
May 22, 2010·Cancer Immunology, Immunotherapy : CII·Flávia Gomes de Góes RochaMaria Helena Bellini
Sep 4, 2010·International Journal of Urology : Official Journal of the Japanese Urological Association·Tsunenori KondoKazunari Tanabe
Feb 24, 2011·The Journal of Gene Medicine·Flávia Gomes de Góes RochaMaria H Bellini

❮ Previous
Next ❯

Citations

Aug 13, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Marina de Souza BragaMaria Helena Bellini
Apr 6, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Karen FoguerMaria Helena Bellini
Sep 15, 2015·Biochimica Et Biophysica Acta·Amit WaliaDimitri T Azar
Nov 2, 2014·EMBO Molecular Medicine·John Ml EbosRobert S Kerbel
Feb 25, 2020·Translational Oncology·Paweł SobczukAnna M Czarnecka

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.